Robert Huddart

31.9k total citations · 9 hit papers
388 papers, 14.9k citations indexed

About

Robert Huddart is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Robert Huddart has authored 388 papers receiving a total of 14.9k indexed citations (citations by other indexed papers that have themselves been cited), including 267 papers in Surgery, 173 papers in Pulmonary and Respiratory Medicine and 70 papers in Oncology. Recurrent topics in Robert Huddart's work include Testicular diseases and treatments (137 papers), Bladder and Urothelial Cancer Treatments (111 papers) and Prostate Cancer Diagnosis and Treatment (67 papers). Robert Huddart is often cited by papers focused on Testicular diseases and treatments (137 papers), Bladder and Urothelial Cancer Treatments (111 papers) and Prostate Cancer Diagnosis and Treatment (67 papers). Robert Huddart collaborates with scholars based in United Kingdom, United States and Canada. Robert Huddart's co-authors include David P. Dearnaley, A. Horwich, A. Norman, Alan Horwich, Janet Shipley, Emma Hall, Vincent Khoo, Chris Parker, Rosalind A. Eeles and J. Nicholls and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Robert Huddart

375 papers receiving 14.6k citations

Hit Papers

Escalated-dose versus sta... 2007 2026 2013 2019 2007 2012 2018 2012 2014 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
    2007 686 citations David P. Dearnaley, Robert Huddart et al. profile →
  2. Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
    2012 617 citations Nicholas D. James, Syed A. Hussain et al. profile →
  3. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)
    2018 397 citations S. Hafeez, Robert Huddart et al. European Urology profile →
  4. Stereotactic body radiotherapy for oligometastases
    2012 374 citations Alison Tree, Vincent Khoo et al. profile →
  5. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial
    2014 344 citations David P. Dearnaley, Vincent Khoo et al. profile →
  6. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2021 309 citations Robert Huddart, Yohann Loriot et al. Annals of Oncology profile →
  7. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
    2023 132 citations Yohann Loriot, Nobuaki Matsubara et al. profile →
  8. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 99 citations Daniel M. Berney, Gedske Daugaard et al. Annals of Oncology profile →
  9. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma
    2024 74 citations Robert Huddart, Yohann Loriot et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Robert Huddart 7.8k 5.6k 3.2k 2.7k 2.0k 388 14.9k
Padraig Warde 5.1k 0.7× 9.7k 1.7× 3.2k 1.0× 1.7k 0.7× 3.4k 1.7× 420 16.2k
Hans von der Maase 8.2k 1.1× 3.4k 0.6× 4.8k 1.5× 2.8k 1.1× 704 0.3× 214 13.6k
Harm van Tinteren 6.1k 0.8× 5.7k 1.0× 5.2k 1.6× 3.0k 1.1× 335 0.2× 340 17.1k
Axel Heidenreich 7.2k 0.9× 14.0k 2.5× 3.6k 1.1× 3.1k 1.2× 641 0.3× 716 21.5k
Jason A. Efstathiou 4.9k 0.6× 5.0k 0.9× 2.3k 0.7× 1.9k 0.7× 1.8k 0.9× 314 11.4k
Louis L. Pisters 4.5k 0.6× 7.1k 1.3× 2.5k 0.8× 1.9k 0.7× 734 0.4× 299 12.3k
A. Norman 5.2k 0.7× 5.9k 1.0× 5.9k 1.8× 1.2k 0.4× 840 0.4× 138 12.3k
Andrew J. Stephenson 3.4k 0.4× 7.7k 1.4× 1.2k 0.4× 1.7k 0.6× 850 0.4× 242 10.5k
William U. Shipley 9.9k 1.3× 14.2k 2.5× 3.8k 1.2× 1.9k 0.7× 5.4k 2.7× 401 23.8k
Michael A.S. Jewett 6.1k 0.8× 8.9k 1.6× 2.0k 0.6× 6.5k 2.4× 163 0.1× 418 15.7k

Countries citing papers authored by Robert Huddart

Since Specialization
Citations

This map shows the geographic impact of Robert Huddart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Huddart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Huddart more than expected).

Fields of papers citing papers by Robert Huddart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Huddart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Huddart. The network helps show where Robert Huddart may publish in the future.

Co-authorship network of co-authors of Robert Huddart

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Huddart. A scholar is included among the top collaborators of Robert Huddart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Huddart. Robert Huddart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Raggi, Daniele, Filippo Pederzoli, Alberto Martini, et al.. (2025). HER2 and urothelial carcinoma: current understanding and future directions. Nature Reviews Urology. 23(2). 110–132. 1 indexed citations
2.
3.
Alexander, S., Helen Barnes, Robert Huddart, et al.. (2024). 1212: Assessing a unique bladder preparation protocol for patients undergoing prostate cancer radiotherapy. Radiotherapy and Oncology. 194. S5525–S5528. 1 indexed citations
4.
Huddart, Robert, et al.. (2024). 697P The Empower Pathway overview: An innovative approach to delivering personalised care for testicular cancer survivors. Annals of Oncology. 35. S539–S539. 1 indexed citations
5.
6.
Alexander, S., Trina Herbert, Robert Huddart, et al.. (2023). Evaluation of non-vendor magnetic resonance imaging sequences for use in bladder cancer magnetic resonance image guided radiotherapy. Physics and Imaging in Radiation Oncology. 27. 100481–100481. 1 indexed citations
7.
Philipps, L., Núria Porta, Nicholas D. James, et al.. (2023). Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer. Clinical Oncology. 35(5). e336–e343. 2 indexed citations
8.
Sternberg, Cora N., Yohann Loriot, Ernest Choy, et al.. (2023). Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract carcinoma (UTC).. Journal of Clinical Oncology. 41(16_suppl). 4569–4569. 1 indexed citations
9.
Hussain, Syed A., J.F. Lester, Richard A. Jackson, et al.. (2022). Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 20 indexed citations
10.
Trendowski, Matthew R., Emma Wilkinson, Paul C. Dinh, et al.. (2022). Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Medicine. 11(14). 2801–2816. 11 indexed citations
11.
Crabb, Simon J., Sarah Danson, James W.F. Catto, et al.. (2021). Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). Clinical Cancer Research. 27(7). 1882–1892. 17 indexed citations
12.
Hafeez, S., K. Warren-Oseni, Vibeke Hansen, et al.. (2020). Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance. BMJ Open. 10(5). e037134–e037134. 21 indexed citations
13.
Brand, Douglas, David P. Dearnaley, Rosalind A. Eeles, et al.. (2019). Patterns of recurrence after prostate bed radiotherapy. Radiotherapy and Oncology. 141. 174–180. 15 indexed citations
14.
Loveday, Chey, Amit Sud, Kevin Litchfield, et al.. (2019). Runs of homozygosity and testicular cancer risk. Andrology. 7(4). 555–564. 4 indexed citations
15.
Litchfield, Kevin, Chey Loveday, Max Levy, et al.. (2018). Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene. European Urology. 73(6). 828–831. 44 indexed citations
16.
Gilbert, Duncan C., Reem Al‐Saadi, Khin Thway, et al.. (2015). Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. Clinical Cancer Research. 22(5). 1265–1273. 18 indexed citations
17.
18.
Huddart, Robert, Anwar R. Padhani, G.M. Mead, et al.. (2007). 18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: Preliminary report of MRC trial TE22 - The NCRI testis tumour clinical study group. UCL Discovery (University College London). 5 indexed citations
19.
Muro, Xavier García del, Robert Huddart, Jorge Aparicio, et al.. (2007). Phase II multicenter study of imatinib in patients with chemorefractory germ cell tumors that express c-kit.. Cancer Research. 67. 2648–2648. 12 indexed citations
20.
Staffurth, J., Elizabeth Adams, Stephen Breen, et al.. (2005). Target Volume Definition for Intensity Modulated Whole Pelvic Radiotherapy (IMWPRT). International Journal of Radiation Oncology*Biology*Physics. 63. S332–S333. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Padraig Warde Breakdown of academic impact, for papers by Hans von der Maase Breakdown of academic impact, for papers by Harm van Tinteren Breakdown of academic impact, for papers by Axel Heidenreich Breakdown of academic impact, for papers by Jason A. Efstathiou Breakdown of academic impact, for papers by Louis L. Pisters Breakdown of academic impact, for papers by A. Norman Breakdown of academic impact, for papers by Andrew J. Stephenson Breakdown of academic impact, for papers by William U. Shipley Breakdown of academic impact, for papers by Michael A.S. Jewett
Rankless by CCL
2026